CoChat

Outstanding Scientific Achievement Award Lecture 2011: Defeating Diabesity

Open access

The DOI matches its Crossref record, with a small difference in title or year; 28 of the 28 references it cites were found in a registry or an index.

Abstract

2011 Outstanding Scientific Achievement Award.The award was presented at the Association's 71st Scientific Sessions

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db12-0272

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. After two decades of decimation, only a few large pharmaceutical companies remain capable of conducting multiple parallel phase-3 drug trials (boldface indicates companies that are currently still in operation). The downward trend continues and may turn into a bottleneck for late-stage development of potential diabetes and obesity breakthrough drugs.
FIG. 1. After two decades of decimation, only a few large pharmaceutical companies remain capable of conducting multiple parallel phase-3 drug trials (boldface indicates companies that are currently still in operation). The downward trend continues and may turn into a bottleneck for late-stage development of potential diabetes and obesity breakthrough drugs.CC BY-NC-ND · PubMed Central
FIG. 2. Proof of metabolic in vivo activity beyond GLP-1 agonism in coagonists with additional imbalanced and balanced glucagon coagonism. Effects on body weight and body fat in diet-induced obese mice genetically engineered to lack the receptor for GLP-1. BW, body weight. ***P < 0.001. Modified from ref. (19).
FIG. 2. Proof of metabolic in vivo activity beyond GLP-1 agonism in coagonists with additional imbalanced and balanced glucagon coagonism. Effects on body weight and body fat in diet-induced obese mice genetically engineered to lack the receptor for GLP-1. BW, body weight. ***P < 0.001. Modified from ref. (19).CC BY-NC-ND · PubMed Central
FIG. 3. Principle of novel drug candidates for the treatment of diabetes and obesity based on single molecule peptide coagonism. A single natural peptide hormone (in this example, glucagon) is engineered using minimal chemical changes to turn it into a “master key,” which activates additional receptors (as in this example, GLP-1R). The size of the resulting molecule is similar to that of a single agonist peptide (e.g., GIP), rather than a two-peptide chimera. Additional changes can convey protection from protease cleavage and add longer lasting activity by changing pharmacokinetic profiles. (Fig. 3 animation is available online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0272/-/DC1.)
FIG. 3. Principle of novel drug candidates for the treatment of diabetes and obesity based on single molecule peptide coagonism. A single natural peptide hormone (in this example, glucagon) is engineered using minimal chemical changes to turn it into a “master key,” which activates additional receptors (as in this example, GLP-1R). The size of the resulting molecule is similar to that of a single agonist peptide (e.g., GIP), rather than a two-peptide chimera. Additional changes can convey protection from protease cleavage and add longer lasting activity by changing pharmacokinetic profiles. (Fig. 3 animation is available online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db12-0272/-/DC1.)CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 32

Metadata

Authors
Tschöp, M. H., & DiMarchi, R. D.
Affiliations
  • Helmholtz Munich (DE)
  • Indiana University Bloomington (US)
Corresponding author
Tschöp, Matthias H.
Venue
Diabetes
Published
2012-05-14
Volume
61
Issue
6
Pages
1309-1314
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2109064292
Cited by
32
References
27
Citations by year
2023: 1 · 2020: 1 · 2019: 1 · 2017: 3 · 2016: 3 · 2015: 5 · 2014: 7 · 2013: 9 · 2012: 2
FWCI
5.90
Type
journal article
Language
en
Open access
Locations
  • Diabetes (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • mediaTUM (Technical University of Munich) (submittedVersion)
  • Site cant be reached (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
diabesity, obesity, obesity-related diabetes
MeSH terms
Awards and Prizes, Diabetes Mellitus, Type 2, Humans, Obesity, Societies, Scientific, Precision Medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.